Abbott
ABT

$113.86

0.67%

Market Cap: $198B

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more call options, than puts

Call options by funds: $1.03B | Put options by funds: $857M

0.59% less ownership

Funds ownership: 76.28% [Q1] → 75.69% (-0.59%) [Q2]

5% less repeat investments, than reductions

Existing positions increased: 1,105 | Existing positions reduced: 1,162

2% less funds holding

Funds holding: 2,836 [Q1] → 2,785 (-51) [Q2]

9% less capital invested

Capital invested by funds: $150B [Q1] → $137B (-$13.1B) [Q2]

26% less first-time investments, than exits

New positions opened: 146 | Existing positions closed: 197

33% less funds holding in top 10

Funds holding in top 10: 86 [Q1] → 58 (-28) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$120

5%

upside

Avg. target

$130

14%

upside

High target

$143

26%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Citigroup Joanna Wiensch 100% 1-year accuracy 2 / 2 met price target	12%upside $127	Buy Maintained	22 Aug 2024
Barclays Matt Miksic 59% 1-year accuracy 17 / 29 met price target	26%upside $143	Overweight Maintained	29 Jul 2024
Evercore ISI Group Vijay Kumar 90% 1-year accuracy 27 / 30 met price target	5%upside $120	Outperform Maintained	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 35 articles about ABT published over the past 30 days

Zacks Investment Research

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

Zacks Investment Research

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

Zacks Investment Research

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott launches over-the-counter continuous glucose monitor in the US

Abbott has launched its over-the-counter continuous glucose monitoring system Lingo in the United States, the company said on Thursday.

Abbott launches over-the-counter continuous glucose monitor in the US

Investors Business Daily

Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device

Abbott Laboratories launches its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.

Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device

Abbott launches its first over-the-counter continuous glucose monitor in the U.S.

Abbott Laboratories on Thursday announced its over-the-counter continuous glucose monitor Lingo is available in the U.S. Lingo can be purchased without a prescription, and it's intended for adults who do not take insulin that want to improve their overall health and wellness.

Abbott launches its first over-the-counter continuous glucose monitor in the U.S.

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.

Designed for people interested in improving their overall health and wellness Provides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressors Available without a prescription; explore different purchase options at www.hellolingo.com ABBOTT PARK, Ill., Sept. 5, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription.

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.

Zacks Investment Research

Should You Continue to Retain ABT Stock in Your Portfolio Now?

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating condition Approximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder.

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Zacks Investment Research

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know

In the latest trading session, Abbott (ABT) closed at $114.66, marking a +1.23% move from the previous day.

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know

See News Rankings